Does indoor air make eczema worse?

For several factors the answer is yes. In adults, long-term exposure to fine particles is associated with newly diagnosed atopic dermatitis — an odds ratio of 2.30 (1.25–4.25) per 10 µg/m³ of PM₂.₅, and 1.30 (1.04–1.61) for nitrogen dioxide, from a meta-analysis of twenty studies. In children, indoor volatile compounds track with more severe disease, though on thinner evidence — two studies, both with confidence intervals that include zero. The reverse direction has been tested too, but only weakly: one uncontrolled study found less severe disease after children spent three to four days in a low-emission room. What is not established is that any of this causes eczema on its own — the disease is genetic and immunological first, and indoor air acts on a skin barrier that is already impaired.

Why the skin is a route of exposure

Eczema is usually discussed as a skin disease and indoor air as a lung problem, so the two rarely meet in one conversation. But airborne particles and reactive gases deposit on skin, and a barrier that already leaks water outward also lets more in. That is why the evidence below is about skin, not breathing, and why a bedroom matters more than an office — it is where the exposure lasts eight hours a night on bare skin.

How strong is the evidence

Strongest for fine particles and nitrogen dioxide in adults: a meta-analysis of twenty studies, which is a design that can be wrong about the size of an effect but rarely about its direction. Weaker, and in children, for indoor volatile compounds: two Claims graded D. In one day-care cohort a rise in indoor toluene was followed two days later by more symptoms, while benzene in the same study was borderline and not statistically significant (C-0014); in a cross-sectional study of 149 children, raised urinary metabolites of volatile compounds were more common in those with the disease, which measures the substance in urine rather than in air (C-0012). Consistent in direction, wide in magnitude, and neither strong enough to carry a recommendation on its own. Weakest, and honestly reported as such, for the intervention studies: single trials with small numbers, which is why the entries below are graded rather than listed. Nothing here is a causal claim; the disease starts in the skin barrier and the immune system, and indoor air acts on that.

Every row is a Finding — one sentence as printed in one study, with its page — and every interpretation is a Claim of Coridum’s, graded A to D by the study designs behind it. Where the evidence points both ways, the counter-evidence is named on the Claim.

What to change first

The order follows the evidence, not the price list — and the honest headline is that no measure here has strong evidence behind it. Removing sources is the one with the most direct test: children with atopic dermatitis had less severe disease after three to four days in a low-emission room (C-0013). That study had no control group, the improvement was measured before and after, and the same study found no significant overall correlation between the room’s air quality and severity — which is why the Claim is graded D and carries its counter-evidence with it. Taken for what it is, it points at new furniture, new flooring and freshly renovated rooms — the same wood-based panels and laminate flooring that raise indoor formaldehyde after installation.

Ventilation does the same job for what is already in the air, and it is the only measure that works while a source is still emitting. Air filtration comes last: one study, 24 weeks, about 18 % lower severity (C-0010) — worth trying, not worth promising. Two single studies pointing the same way is a reason to measure your own room, not a reason to expect a result.

One thing worth naming because it is often assumed: gas cooking. Indoor fuel combustion shows no conclusive link (C-0006). The pooled estimate looked positive until publication bias was corrected, and then it fell to almost exactly no effect. Reporting that honestly is more useful than adding one more suspect to the list.

What would settle it

Almost every study here measured exposure in one place and asked about symptoms separately, which is why the confidence intervals are wide and why two systematic reviews can disagree — one based on measured exposure, one on what people reported about themselves. What would settle it is exposure assessment at the person rather than at the wall: continuous measurement in the bedroom of a child whose severity is scored on the same days. That is a study design, not a wish, and it is the one Coridum’s own measurements are meant to feed into.